Amphastar Pharmaceuticals AMPH Payments Of Debt Issuance Costs

Payments Of Debt Issuance Costs at other companies

HRO

HarrowHROW

——

BioCryst PharmaceuticalsBCRX

——

Other financials

Income statement

See full

Revenue$171.2M+0.4%

Gross profit$70.3M-17.5%

Operating income$13.6M-63.5%

Net income$6.4M-74.6%

EPS (diluted)$0.14-72.5%

Balance sheet

See full

Cash & equivalents$170.9M-6.5%

Total debt$686.6M+5.2%

Total equity$445.5M—

Total assets$1.6B+1.3%

Cash flow

See full

Operating cash flow$47.8M+36.4%

CapEx$9.5M-11.1%

Free cash flow$38.3M+57.2%

Valuation

See full

Market cap$927.72M-19.9%

Enterprise value$1.44B-11.3%

P/E11.7×+3.5×

P/S1.3×-0.3×

Profitability

See full

Gross margin47.3%-3.2pp

Operating margin16.2%-10.4pp

Net margin11%-8.4pp

FCF margin18.8%-1.8pp

Returns & leverage

See full

Return on equity14.7%—

Debt / equity0.2×—

Current ratio3.9×+0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Amphastar Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's payments of debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amphastar Pharmaceuticals's payments of debt issuance costs?: Amphastar Pharmaceuticals (AMPH) reported payments of debt issuance costs of $8K in Q4 2025.